Can Aliskiren be Considered as a New Novel Drug for Hypertension?
| Autor: | Adnan Bashir Bhatti, Zarine Anwar Gazali |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Drug
aliskerin medicine.medical_specialty hypertension Combination therapy biology business.industry media_common.quotation_subject General Engineering Angiotensin-converting enzyme Aliskiren Pharmacology Direct Renin chemistry.chemical_compound chemistry angiotensin receptor blockade medicine biology.protein Internal Medicine Effective treatment Intensive care medicine business Adverse effect media_common angiotensin converting enzyme |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| Popis: | Hypertension is one of the most common causes of death across the globe. Many trials and drugs have been used for controlling the debilitating effects of hypertension. One such new class of drug is direct renin inhibitors (DRI), e.g., aliskiren, which block the renin-angiotensin system (RAS). It blocks the very first step in the RAS system. Multiple trials have been carried out debating the outcome of monotherapy and combination therapy with other classes of hypertensive drugs. Focus on compliance, adverse effects, and the cost have also been in the news. Extensive studies are still needed to justify the clinical use of a DRI in the effective treatment of hypertension. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|